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Background. Human noroviruses are among the most common enteropathogens globally, and are a leading
cause of infant diarrhea in developing countries. However, data measuring the impact of norovirus at the communi-
ty level are sparse.
Methods. We followed a birth cohort of children to estimate norovirus infection and diarrhea incidence in a Pe-
ruvian community. Stool samples from diarrheal episodes and randomly selected nondiarrheal samples were tested
by polymerase chain reaction for norovirus genogroup and genotype. Excretion duration and rotavirus coinfection
were evaluated in a subset of episodes.
Results. Two hundred twenty and 189 children were followed to 1 and 2 years of age, respectively. By 1 year,
80% (95% conﬁdence interval [CI], 75%–85%) experienced at least 1 norovirus infection and by 2 years, 71% (95%
CI, 65%–77%) had at least 1 episode of norovirus-associated diarrhea. Genogroup II (GII) infections were 3 times
more frequent than genogroup 1 (GI) infections. Eighteen genotypes were found; GII genotype 4 accounted for
41%. Median excretion duration was 34.5 days for GII vs 8.5 days for GI infection (P = .0006). Repeat infections by
the same genogroup were common, but repeat infections by the same genotype were rare. Mean length-for-age z
score at 12 months was lower among children with prior norovirus infection compared to uninfected children (coef-
ﬁcient: −0.33 [95% CI, −.65 to −.01]; P = .04); the effect persisted at 24 months.
Conclusions. Norovirus infection occurs early in life and children experience serial infections with multiple ge-
notypes, suggesting genotype-speciﬁc immunity. An effective vaccine would have a substantial impact on morbidity,
but may need to target multiple genotypes.
Keywords. norovirus; infant diarrhea; gastroenteritis; birth cohort; natural infection.
Noroviruses, RNA viruses with >36 recognized geno-
types [1, 2], are the leading cause of gastroenteritis
outbreaks [3, 4]. Noroviruses have recently been recog-
nized as the second most common etiology of infant di-
arrhea and hospitalization for diarrhea, and cause an
estimated 200 000 child deaths annually in developing
countries [5]. With rotavirus vaccine introduction, the
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relative importance of norovirus is increasing [6, 7]. However,
the need for reverse transcription polymerase chain reaction
(RT-PCR) has impeded studies in resource-limited settings.
The impact of norovirus at the community level is poorly un-
derstood, because few population- or clinic-based studies have
been conducted [8–12]. In this study, the ﬁrst community-
based birth cohort to examine norovirus epidemiology, we
followed Peruvian infants to investigate norovirus incidence,
determinants of norovirus diarrhea, excretion duration, and
evidence for protection from subsequent infection.
METHODS
Ethics Statement
The study was approved by the institutional review boards of
Asociación Benéﬁca PRISMA, Universidad Peruana Cayetano
Heredia (UPCH), Johns Hopkins University, the Centers for
Disease Control and Prevention (CDC), and the European Union.
Each woman provided written informed consent for her infant.
Recruitment and Data Collection
Participants were recruited in Las Pampas de San Juan de Mira-
ﬂores, a shantytown with approximately 50 000 inhabitants in
southern Lima. Pregnant women and those with newborns
younger than 3 months were randomly selected from a com-
plete community census. Exclusion criteria were hospitalization
for >1 month at birth, any congenital defect, twin birth, and
birth weight <1500 g. None of the participants received rotavi-
rus immunization; all were beyond the eligible age when it was
introduced in Lima. From June 2007 to April 2011, ﬁeld
workers visited each household twice weekly to compile a daily
record of fever, vomiting, frequency of liquid or semiliquid
stools, and breastfeeding status (categorized as exclusive breast-
feeding, formula only, mix of formula and breast milk, or
weaned). Length and weight were measured weekly until 2
months and then monthly [13]. Stool samples were collected
weekly, regardless of symptoms. One specimen was requested
during each diarrheal episode. Samples were transported to
UPCH within 12 hours for storage at −50°C.
Sample Selection
Norovirus testing was conducted in all specimens from diar-
rheal episodes and a random sample of nondiarrheal stools.
One nondiarrheal specimen per child per month was tested in
the ﬁrst year of life. Due to resource limitations, in the second
year of life, testing was conducted in 2 nondiarrheal samples
frequency-matched by month with the corresponding diarrheal
stools. Real-time RT-PCR for rotavirus [14] was performed in
an age-stratiﬁed random sample from each of the following
groups: norovirus-positive with and without diarrhea; norovi-
rus-negative with and without diarrhea. To evaluate excretion
duration, we selected an age-stratiﬁed random sample of 46
norovirus-positive index specimens and tested weekly speci-
mens collected before and after the index specimens. These
samples were selected blindly and not selected by genotype. We
deﬁned the end of an infection episode when 2 sequential spec-
imens were negative. The duration of excretion were deﬁned as
the dates between the ﬁrst and last positive specimens.
Deﬁnitions
A day of diarrhea was deﬁned by the presence of ≥3 liquid or
semiliquid stools in 24 hours. For infants younger than 2 months,
the deﬁnition was based on the mother’s or caretaker’s assess-
ment that the child had diarrhea [15]. An episode ended when
the child had 2 consecutive days without diarrhea. Weaning
was deﬁned as breastfeeding interruption for 7 days or more.
Norovirus was diagnosed by positive real-time RT-PCR
results. Infection with a different genotype at any time was con-
sidered a new infection. The same genogroup or genotype de-
tected after ≥30 days with 2 intervening negative samples was
considered a new infection. If only 1 negative sample existed, a
60-day interval was required to deﬁne a new infection. “Norovirus-
associated diarrhea” was deﬁned based on positive results by
PCR in a stool taken during or within 7 days of the beginning
or end of the diarrheal episode. Diarrhea onset date was
deﬁned as the start date for symptomatic infection. An “asymp-
tomatic” infection occurred when no symptoms were reported
within 7 days of the positive specimen that deﬁned the begin-
ning of the infection episode. If positive results were found in a
nondiarrheal specimen but diarrhea occurred within 30 days or
vomiting within 7 days without norovirus testing, the episode
was coded as “undeﬁned.”
Real-time RT-PCR and Genotyping
Aliquots of 0.1 g (formed) or 0.1 mL (watery) stools were resus-
pended to 1 mL and RNA was extracted using silica particles
with guanidinium thiocyanate [16]. A segment of the ORF1–
ORF2 junction was ampliﬁed by TaqMan real-time RT-PCR,
using published primers and probes for genogroups I (GI) and
II (GII) [17]. The detection limit was determined by standard
curves using 10-fold serial dilutions (106 to 100) of GII.4 and
GI.3 RNA transcripts provided by the National Calicivirus Lab-
oratory, CDC. The detection limit was 10 copies corresponding
to cycle threshold (Ct) 37 for GI and 38 for GII.
Real-time PCR–positive samples were genotyped by conven-
tional PCR targeting the capsid N/S domain (primers G1SKF/
G1SKR for GI, G2SKF/G2SKR for GII) [18]. DNA sequences
were assembled with ChromasPro (Technelysium Pty Ltd,
Tewantin, Australia), aligned with ClustalX (http://www.clustal.
org). Genotypes and GII.4 variants were identiﬁed using
NoroNet (http://www.noronet.nl) [19].
484 • CID 2014:58 (15 February) • Saito et al
Statistical Analysis
Cumulative incidence rates were estimated by Kaplan-Meier
survival analyses. Analyses of asymptomatic infection focused
on infants up to 12 months due to the smaller number of non-
diarrheal stools tested in the second year of life. To evaluate
protection associated with previous norovirus infections, we
used Cox proportional hazard models with the Breslow method
for handling ties [20, 21]. We used logistic regression with gen-
eralized estimating equations to test associations with diarrhea
during norovirus infection. Variables with P < .1 in univariable
analyses were tested by stepwise selection in multivariable
models. We also performed a cross-sectional analysis to esti-
mate the unadjusted attributable fraction comparing the preva-
lence of norovirus in diarrhea and nondiarrhea samples. (the
proportion of diarrhea theoretically eliminated if norovirus
were eliminated) [22]. Episode duration, maximum daily
number of diarrheal stools, days of vomiting, and reported
fever were compared by genogroup and GII genotype using the
χ
2 test or Mann-Whitney U test. The same variables were com-
pared for the ﬁrst and second infection within the same child.
To evaluate associations between norovirus infection and
growth, multiple linear regression models were generated with
the outcome length-for-age and weight-for-age z scores (LAZ
and WAZ, respectively) [13]. Analyses adjusted for breastfeed-
ing prevalence included data only from children with ≥6
months of follow-up. To test if the observed frequencies of ge-
notypes in repeated infections were signiﬁcantly different than
expected by chance, we generated a simulation of 1 million
children with a mean of 3 norovirus infections randomly dis-
tributed according to the genotype prevalence found in the
study population. The genotype frequencies expected by
chance were compared with the observed frequencies by a 2-
sample proportion test for a binomial distribution. Analyses
were performed using Stata software, version 12 (StataCorp,
College Station, Texas).
RESULTS
A total of 291 children participated, yielding 4978 child-
months of follow-up. Median age at recruitment was 19 days
(range, 0–97 days). The number of children followed to 6
months, 1 year, and 2 years of age was 256, 220, and 189, re-
spectively. Of study households, 89% had continuous indoor
running water and 91% had an indoor toilet. Background char-
acteristics were comparable for the 189 children who completed
follow-up and 102 children who withdrew before the study
ended (Supplementary Table 1). Norovirus testing was per-
formed in 1495 diarrheal and 3690 randomly selected nondiar-
rheal stools. An additional 789 stools included in the random
selection were found to have been collected within 7 days of a
diarrheal episode; data from these specimens were included in
norovirus diarrhea incidence analyses, but not in calculation of
the attributable fraction (see below).
Norovirus Incidence
In total, 607 norovirus infections were identiﬁed (140 [23.1%]
GI, 460 [75.8%] GII, and 7 [1.1%] GI/GII mixed infections).
Two hundred seventy-ﬁve (45.3%; 60 GI, 211 GII, 4 GI/GII
mixed) infections were associated with diarrhea.
In the ﬁrst year of life, 321 infections occurred during 2694
child-months of follow-up. The incidence rate was 8.6 (95%
conﬁdence interval [CI], 7.1–10.4) and 15.7 (95% CI, 13.6–
18.1) per 100 child-months for ages 0–5 months and 6–11
months, respectively. Eighty percent of children had at least 1
infection and 38% had at least 2 infections by 1 year of age
(Figure 1A). Of 208 ﬁrst infections in the ﬁrst year of life, 46%
(95) were asymptomatic, 33% (69) symptomatic, and 21% (44)
undeﬁned. A signiﬁcantly higher percentage of infections was
asymptomatic among infants younger than 6 months (55%
[66/119]) compared to those aged 6–11 months (36% [73/202])
(adjusted odds ratio [AOR], 2.2 [95% CI, 1.3–3.8]; P < .001).
Exclusive breastfeeding during age 3–5 months was protective
(AOR, 0.5 [95% CI, .3–.9]; P = .03). There was no signiﬁcant
difference in diarrhea risk between GI and GII infections
(AOR, 1.6 [95% CI, .8–3.0]).
Among infants aged 0–5, 6–11, and 12–24 months, norovi-
rus-associated diarrhea incidence was 2.4 (95% CI, 1.7–3.4), 6.6
(95% CI, 2.1–8.0), and 7.0 (95% CI, 6.1–8.4) per 100 child-
months, respectively. At least 1 episode of norovirus-associated
diarrhea occurred in 38% and 71% of children by age 1 and 2
years, respectively (Figure 1B).
The cross-sectional analysis of stool prevalence included
data from 1495 diarrheal and 3690 nondiarrheal stools. Norovi-
rus occurred in 22.8% (95% CI, 20.7%–25.0% [341/1495]) of
diarrheal stools and 13.3% (95% CI, 12.2%–14.4% [491/3690])
of nondiarrheal stools. The association of norovirus with diar-
rhea was stronger in the second (odds ratio [OR], 2.8 [95% CI,
2.2–3.5]) than the ﬁrst year of life (0–5 months: OR, 1.6 [95%
CI, .9–1.8]; 6–11 months: OR, 1.6 [95% CI, 1.2–2.1]). The nor-
ovirus attributable fraction was 7.8% in the ﬁrst year and 23.1%
in the second year of life (Figure 2). Ct values were lower in
diarrheal than nondiarrheal samples (GI: median, 28.2 vs 31.0
[P < .066]; GII: median, 26.4 vs 30.1 [P = .0001], respectively;
Supplementary Figure 1).
Rotavirus Coinfection
Rotavirus occurred in 3.7% (2/54) and 7.4% (4/54) of asymp-
tomatic and diarrheal norovirus-positive specimens, and 17.2%
(10/58) and 11.6% (8/69) of asymptomatic and diarrheal noro-
virus-negative specimens, respectively. Among the 4 diarrheal
episodes with both pathogens, rotavirus was the more likely eti-
ology in 1 (18.1 vs GI 27.8 for rotavirus vs norovirus) and
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norovirus in 2 episodes based on relative Ct values (37.8 vs GII
25.9 and 39.0 vs GI 22.4); the fourth episode had relatively high
Ct values in both (37.7 vs GII 36.4) [23].
Protection Associated With Previous Infection
One or more previous norovirus infections signiﬁcantly de-
creased the risk of subsequent norovirus infection compared to
no previous infection (Table 1). GII infection conferred
signiﬁcant protection against subsequent GII infection and di-
arrhea, but no such effect was seen for GI infection against later
GI infection or diarrhea.
Genotypes
Of 769 real-time RT-PCR positive specimens tested, 573 (75%)
were ampliﬁed by conventional PCR and 535 had readable se-
quences. In total, 18 genotypes were identiﬁed from 347 infec-
tion episodes (Supplementary Table 2). The most frequent
genotype, GII.4, occurred in 141 (40.6%) typed infection epi-
sodes (77 diarrheal, 39 asymptomatic, and 25 undeﬁned). GII.4
was more frequent in symptomatic (49/90 [54%]) than asymp-
tomatic (36/90 [40%]) infections in the ﬁrst year of life (P =
.0523). Four GII.4 variants (2006b [77]; 2007 [52]; 2008 [11];
and 2010 [1]) were detected.
Overall, 81 children had 1, 58 had 2, 52 had 3, and 53 had 4–
8 norovirus infections detected. Repeat infection by the same
genogroup was common (34 GI, 231 GII). However, of the 151
sets of repeat infections with genotype data, only 9 (6.0%) were
of the same genotype (1 GI.5, 7 GII.4, and 1 GII.6). Among 7
sets with repeat GII.4 infection, 2 were by the same variant
(one each for 2006b and 2007), and 5 by different variants
(three 2006b–2007, two 2006b–2008). Thus, of 151 repeat in-
fections, 147 (97%) were by a different genotype or GII.4
variant. The observed frequency of repeat infection was signiﬁ-
cantly lower than expected by chance for GII.6, GII.4 2006b,
and GII.4 2007 (P = .0063, P < .0001, and P = .0072, respective-
ly), but not for GI.5, GII.4 2008, and GII.4 2010.
Figure 2. Prevalence of norovirus in diarrheal and nondiarrheal stool
samples by age. Prevalences are based on cross-sectional analysis of nor-
ovirus polymerase chain reaction in 1495 specimens collected during diar-
rheal episodes and 3690 randomly selected nondiarrheal specimens; 789
specimens collected within 7 days of diarrhea were excluded.
Figure 1. Cumulative incidence of ﬁrst and subsequent norovirus-associated infection and diarrhea in a birth cohort of 291 children. A, Survival curves
show cumulative incidence of the ﬁrst through fourth norovirus infections during the ﬁrst year of life. B, Curves show the cumulative incidence of the ﬁrst
through fourth episodes of norovirus diarrhea for children aged 0–2 years. Percentages show the cumulative incidence, and 95% conﬁdence intervals
(shown in brackets) are based on Kaplan-Meier survival analysis.
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Table 1. Changes in Hazard Ratios of Sequential Norovirus Infection by Number of Previous Infections
No. of Previous Infections
No. of Sequential
Episodes
Incidence per
100 Child-moa
Hazard Ratio (95% CI) for Subsequent Eventb
Adjusted P Value
Previous norovirus infection
0 197 12.46 Ref
1 86 12.04 0.74 (.57–.95) .020
≥2 27 11.07 0.58 (.38–.90) .014
Norovirus diarrhea
0 66 4.17 Ref
1 38 5.32 0.79 (.53–1.18) .256
≥2 9 3.69 0.44 (.18–1.10) .079
Asymptomatic infection
0 87 5.50 Ref
1 33 4.62 0.76 (.50–1.15) .135
≥2 11 4.51 0.70 (.38–1.27) .120
Symptom undefined
0 44 2.78 Ref
1 15 2.10 0.54 (.30–.97) .040
≥2 7 2.87 0.62 (.31–1.24) .173
Sequential infection by the same genogroup
Previous GII infection
0 184 10.97 Ref
1 60 8.30 0.55 (.41–.74) <.001
≥2 6 4.32 0.23 (.11–.48) <.001
GII diarrhea
0 67 3.99 Ref
1 26 3.60 0.55 (.34–.87) .011
≥2 2 1.44 0.18 (.05–.68) .012
Previous GI infection
0 56 2.42 Ref
≥1 7 3.07 0.93 (.40–2.18) .629
GI diarrhea
0 17 0.74 Ref
≥1 3 1.31 1.06 (.21–5.26) .944
Background characteristics
Age group
0–5 mo 108 8.61 Ref
6–11 mo 202 15.72 2.12 (1.65–2.73) <.001
Days with exclusive breastfeeding during age 3–5 mo, %
<50% 140 13.47 Ref.
≥50% 170 11.33 0.82 (.66–1.02) .069
Potable water available 24 h/day in household
Yes 262 11.54 Ref.
No 48 17.80 1.59 (1.15–2.20) .005
Season
Winter (June–August) 45 6.66 Ref
Fall (March–May) 67 10.58 1.51 (1.03–2.21) .020
Summer (December–February) 86 15.09 2.18 (1.54–3.09) <.001
Spring (September–November) 112 16.95 2.51 (1.78–3.53) <.001
Abbreviations: CI, confidence interval; GI, genogroup I; GII, genogroup II.
a Follow-up time was 1581 child-months for the group with no previous infections, 714 child-months for those with 1 previous infection, and 244 child-months for
those with ≥2 previous infections. Thirty-five children with <6 months of follow-up were excluded from analysis; these children had 11 norovirus infections.
Therefore, 310 infections were included in this analysis.
b Analyses were adjusted for age (0–5 months and 6–11 months), percentage of days with exclusive breastfeeding during 3–5 months of age, and having running
water in household for 24 hours/day. Analyses of background characteristics were also adjusted for norovirus infection status. Sex, birth weight, mother’s education,
mother’s age, household income, ability to store water, and having toilet with drainagewere not significantly associated with norovirus infection or diarrhea.
c
P values in bold are significant at <.05 level.
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Excretion Duration
Length of viral shedding was comparable in diarrheal (n = 24;
median, 31.5 days) and asymptomatic episodes (n = 14; median,
30 days; P = .83; 8 undeﬁned episodes excluded). Median GII
excretion duration was 34.5 days (n = 34; interquartile range
[IQR], 28–47; max = 98), with 74% (25/34) lasting >30 days and
18% (6/34) >60 days (Figure 3). GI excretion was of shorter du-
ration (n = 12; median, 8.5 days; IQR, 3.5–19.5; max = 49) than
GII (P = .0006). Seven infections yielded positive results only in
the ﬁrst weekly stool (4 GI, 3 GII). In 35 of the 39 remaining epi-
sodes, the lowest Ct values were observed in the ﬁrst or second
week (8 GI, 27 GII). The lowest Ct occurred later than the
second week of excretion in only 4 (9%) episodes (all GII).
Symptoms by Genogroup
Of 275 norovirus-associated diarrhea episodes, 54 were GI and
209 GII only; 4 mixed infections and 8 with incomplete clinical
information were excluded. GII episodes were more likely than
GI episodes to be associated with fever (26% vs 13%, P = .04),
≥3 days of vomiting (9% vs 0%, P = .04), and longer duration
of symptoms (median, 2 days [range, 1–10] vs 3 days [range, 1–
17]; P = .06). The median daily number of diarrheal stools was
4 for both GI and GII (P = .79). GII.4 episodes were more likely
to have longer duration of episodes compared to other GII ge-
notypes (median, 3 days [range, 1–17] vs 2 days [range, 1–10];
P = .047). One study child was admitted to hospital for severe
diarrhea due to norovirus GII.6. Among 163 children with re-
peated norovirus infection, 71 had repeated norovirus diarrhea
and 54 had repeated GII diarrhea. There was no decrease in
Figure 3. Duration of norovirus shedding by real-time reverse transcrip-
tion polymerase chain reaction in 46 randomly selected infection episodes.
The boxes represent 25th percentile, median, and 75th percentile, and the
whiskers show the minimum and maximum duration of shedding in days.
Abbreviations: GI, genogroup I; GII, genogroup II.
Table 2. Effect of Norovirus Infection on Linear Growth Based on Generalized Linear Regression Models for Length-for-Age z Score at
12 Months of Age
Variable LAZ Coefficient 95% CI P Value
No. of NoV infectionsa None Ref. Ref.
≥1 −0.33 (−.65 to −.01) .04
No. of GI infectionsa None Ref. Ref.
≥1 −0.06 (−.36 to −.24) .71
No. of GII infectionsa None Ref. Ref.
≥1 −0.28 (−.57 to −.01) .06
Diarrheal episodes during first year of lifea ≤4 Ref. Ref.
>4 0.05 (−.22 to .31) .73
Days of diarrhea during first year of lifea ≤11 Ref. Ref.
>11 0.05 (−.31 to .22) .74
Birth weight, gb ≤3300 Ref. Ref.
>3300 0.65 (.39 to −.90) <.001
Days of exclusive breastfeeding at age 3–5 mo, %b <50 Ref. Ref.
≥50 −0.28 (−.54 to −.02) .04
Monthly income, USDb 51–150 Ref. Ref.
≥151 0.42 (.10 to .74) .01
Outcome expressed as adjusted LAZ coefficients.
Abbreviations: CI, confidence interval; GI, genogroup I; GII, genogroup II; LAZ, length-for-age z score; NoV, norovirus; USD, US dollars.
a Coefficients were adjusted for exclusive breastfeeding, birth weight, and income.
b Coefficients were adjusted for norovirus infection in addition to the 3 variables above. Of 220 children who completed 1 year of follow-up, 4 were excluded due to
incomplete data on household income or birth weight.
c
P values in bold are significant at <.05 level.
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likelihood of fever, vomiting, maximum number of diarrheal
stools, or symptom duration in second episodes compared with
ﬁrst episodes for all norovirus or only GII episodes.
Norovirus and Linear Growth
Mean LAZ and WAZ at 12 months were signiﬁcantly lower in
children with norovirus infection during the ﬁrst year of life
compared to those not infected, in models adjusted for birth
weight, breastfeeding status, and household income (coefﬁ-
cient: −0.33 [95% CI, −.65 to −.01], P = .04 and −0.55 [95%
CI, −.87 to −.23], P < .01, respectively; Tables 2 and 3). Having
indoor connection of the water for 24 hours daily, having a
toilet, ability to store the water or not, and mother’s education
level were not associated with LAZ or WAZ. Decrease in LAZ
and WAZ at 12 months was more signiﬁcant by GII infection
than by GI. The effect of norovirus and GII infection on LAZ
and WAZ persisted at 24 months (coefﬁcient: −0.43 [95% CI,
−.79 to −.07], P = .02 and –0.40 [95% CI, −.71 to −.08],
P = .01, respectively).
DISCUSSION
Our data represent the ﬁrst population-based norovirus birth
cohort and underscore the importance of this virus as a cause
of endemic diarrhea in young children [5, 24–27]. In this
periurban shantytown, norovirus infected 80% of infants by age
12 months and children had up to 8 infection episodes by age 2
years. The majority of infections during the ﬁrst 6 months were
asymptomatic, possibly reﬂecting the effect of breastfeeding
and transferred maternal antibodies. Infection was more strongly
associated with diarrhea in the second year of life than the ﬁrst.
Genogroup II infections were more frequent, more likely to
cause fever and vomiting, and had longer excretion periods than
GI. As in previous studies, we found that gastroenteritis was as-
sociated with lower Ct values, implying higher viral loads, than
asymptomatic infection [28].
The prolonged shedding shown in this study and others
[8, 29, 30] was remarkable. In our data, 74% of GII infections
lasted >1 month. Because of the long excretion period, we
included stringent requirements to deﬁne the end of infection
episodes and associations with diarrhea. In addition, only a
proportion of weekly surveillance stools were tested. Our
incidence estimates are therefore conservative. Nevertheless, we
found that nearly all children had been infected and 71% had
norovirus diarrhea at least once by age 2 years. The low infec-
tive dose, prolonged excretion, resistance to disinfection, and
multiple routes of transmission [3, 4] combine to make noro-
virus infection nearly universal early in life. Children with
norovirus in their ﬁrst year of life were signiﬁcantly shorter
for their age than those without infection, and at 2 years, this
Table 3. Effect of Norovirus Infection on Linear Growth Based on Generalized Linear Regression Models for Weight-for-Age z Score at
12 Months of Age
Variables WAZ Coefficient 95% CI P Value
No. of NoV infectionsa None Ref. Ref.
≥1 −0.55 (−.87 to −.23) .001
No. of GI infectionsa None Ref. Ref.
≥1 −0.16 (−.47 to .15) .30
No. of GII infectionsa None Ref. Ref.
≥1 −0.42 (−.72 to −.12) .01
Diarrheal episodes during first year of lifea ≤4 Ref. Ref.
>4 −0.05 (−.32 to .22) .70
Days of diarrhea during first year of lifea ≤11 Ref. Ref.
>11 −0.02 (−.28 to .25) .90
Birth weight, gb ≤3300 Ref. Ref.
>3300 0.64 (.38 to .90) <.001
Days of exclusive breastfeeding at age 3–5 mo, %b <50 Ref. Ref.
≥50 −0.36 (−.62 to −.10) .01
Monthly income, USDb 51–150 Ref. Ref.
≥151 0.27 (−.05 to .59) .10
Outcome expressed as adjustedWAZ coefficients.
Abbreviations: CI, confidence interval; GI, genogroup I; GII, genogroup II; NoV, norovirus; USD, US dollars; WAZ, weight-for age z score.
a Coefficients were adjusted for exclusive breastfeeding, birth weight, and income.
b Coefficients were adjusted for norovirus infection in addition to the 3 variables above. Of 220 children who completed 1 year of follow-up, 4 were excluded due to
incomplete data on household income or birth weight.
c
P values in bold are significant at <.05 level.
Multiple Norovirus Infections in Infancy • CID 2014:58 (15 February) • 489
linear growth deﬁcit persisted. Prolonged infection, even when
asymptomatic, may cause subclinical chronic intestinal inﬂam-
mation decreasing nutrient absorption and growth [31].
Among those tested, 7% and 4% of norovirus-positive diarrheal
and nondiarrheal stools were also positive for rotavirus. Limited
testing for other enteric pathogensmeans that some study children
with norovirus likely had undetected copathogens contributing
to their symptoms. Some analyses were limited by the 20% gap
between norovirus episodes identiﬁed by real-time RT-PCR
and those genotyped by the conventional PCR assay. The lower
rate of ampliﬁcation may have resulted from the longer product
targeted by the C capsid PCR, primer-template mismatch, and/
or low viral loads in some specimens [32, 33]. Our typing
method did not include polymerase region type or evaluation
of multiple genotypes [34], which may have resulted in under-
reporting of genotype diversity. Nevertheless, our data conﬁrm
the utility of the C capsid PCR to type the majority of norovi-
ruses [19].
Our data demonstrated a high degree of norovirus genetic
diversity. Repeat infections by the same genogroup were
common, but 97% of repeat infections were by a different geno-
type or GII.4 variant. These data suggest that children may
develop genotype-speciﬁc immunity with only a modest level
of cross-protection even within the genogroup. This observa-
tion will need to be taken into account in development of vac-
cines, which may need to include multiple genotypes to achieve
clinical protection. Furthermore, the observation of repeat in-
fections by different GII.4 variants suggest that molecular mon-
itoring may be necessary to ensure that the most relevant
variants are included in vaccines over time.
In summary, this study demonstrates a high incidence
of multiple norovirus infections with remarkable genetic diver-
sity and prolonged excretion in infants living in a periurban
community. Norovirus is a frequent cause of diarrhea severe
enough for hospitalization [25], with an estimated 200 000
child deaths each year from the virus [5]. Clearly, development
of an effective norovirus vaccine represents the next issue of im-
portance to control diarrheal deaths and hospitalization. A
vaccine based on the Norwalk virus-like particle demonstrated
protection against homotypic experimental challenge; other ap-
proaches are under development. However, our study demon-
strates that children can mount an effective immune response
to norovirus but this response is restricted by viral genotype.
Thus, our data indicate that vaccines may need to include mul-
tiple genotypes and GII.4 variants.
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